TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04913675

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sotrovimab
Description: Sotrovimab 500 mg given by intravenous infusion over 15 min

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: Sotrovimab 500 mg given by intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: Sotrovimab 250 mg given by intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: Sotrovimab 2000 mg given by intravenous infusion over 60 min

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Description: Sotrovimab 2000 mg given by intravenous infusion over 30 min

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Description: Sotrovimab 2000 mg given by intravenous infusion over 15 min

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Description: Sotrovimab up to 3000 mg given by intravenous infusion over 90 min
Study: NCT05934253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine ophthalmic gel 3%
Description: FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroprocaine ophthalmic gel 3%
Description: FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.
Study: NCT04995107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro Press needle
Description: Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed).
Study: NCT05979077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyChart Questionnaire
Description: Prior to clinic visits, families completing the MyChart Questionnaire will enter details about their current management and visit goals, automatically populating their electronic health record for subsequent review/revision by the health care team before and during the visit, reallocating clinic time previously used for data acquisition to individual patient priorities
Study: NCT06093659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulze device with heated tobacco sticks (Product A)
Description: Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulze device with heated tobacco sticks (Product A)
Description: Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulze device with heated tobacco sticks (Product A)
Description: Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulze device with heated tobacco sticks (Product A)
Description: Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulze device with heated tobacco sticks (Product A)
Description: Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
Study: NCT05277012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant capsule and tablet formulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant capsule and tablet formulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant capsule and tablet formulations
Study: NCT06093659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulze device with heated tobacco sticks (Product B)
Description: Product B, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulze device with heated tobacco sticks (Product B)
Description: Product B, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulze device with heated tobacco sticks (Product B)
Description: Product B, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulze device with heated tobacco sticks (Product B)
Description: Product B, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
Study: NCT04937400

Intervention type: OTHER
Intervention: Daily screening for delirium
Description: Each child will be screened twice daily for delirium throughout the transplant hospitalization
Study: NCT05849974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural and fonctional phynotyping
Description: The additioan acts in this research are:~Fonctionnal phenotyping:Retinal sensitivity and fixation stability assessment using microperimetry, assessment of long-term fixation stability Structural Phenotyping: Anterior segment examination with OCT anterior Blood sample collection
Study: NCT04040673

Intervention type: PROCEDURE
Intervention: thyroid lobectomy
Description: routine surgical removal of thyroid for biopsy

Intervention type: PROCEDURE
Intervention: thyroid lobectomy
Description: routine surgical removal of thyroid for biopsy

Intervention type: PROCEDURE
Intervention: thyroid lobectomy
Description: routine surgical removal of thyroid for biopsy

Intervention type: PROCEDURE
Intervention: thyroid lobectomy
Description: routine surgical removal of thyroid for biopsy

Intervention type: PROCEDURE
Intervention: thyroid lobectomy
Description: routine surgical removal of thyroid for biopsy

Intervention type: DEVICE
Intervention: Raman spectroscopy probe measurement
Description: The measurement of Raman spectra from the excised tissue
Study: NCT06510426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif 44 MCG Per 0.5 ML Prefilled Syringe
Description: Rebif 44mcg per 0.5ml administered subcutaneously
Study: NCT04040673

Intervention type: DEVICE
Intervention: Raman spectroscopy probe measurement
Description: The measurement of Raman spectra from the excised tissue

Intervention type: DEVICE
Intervention: Raman spectroscopy probe measurement
Description: The measurement of Raman spectra from the excised tissue

Intervention type: DEVICE
Intervention: Raman spectroscopy probe measurement
Description: The measurement of Raman spectra from the excised tissue

Intervention type: DEVICE
Intervention: Raman spectroscopy probe measurement
Description: The measurement of Raman spectra from the excised tissue
Study: NCT05690191

Intervention type: DRUG
Intervention: Chidamide
Description: Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses

Intervention type: DRUG
Intervention: Lenalidomide
Description: Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle

Intervention type: DRUG
Intervention: Rituximab
Description: Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle
Study: NCT06510426

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.5mL of saline administered subcutaneously
Study: NCT06221111

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rimegepant 75 MG [Nurtec]
Description: placebo controlled trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 MG [Nurtec]
Description: placebo controlled trial
Study: NCT06501222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Remote ischemic conditioning
Description: RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
Study: NCT06102213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010)
Description: PBCLN-010: Human Milk Oligosaccharides (HMO). PBCLN-014: B. infantis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010)
Description: PBCLN-010: Human Milk Oligosaccharides (HMO). PBCLN-014: B. infantis.
Study: NCT05236348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktiia.product-us
Description: The study will collect data from subjects by means of the device under test and collect data from subjects by means of double-auscultation, pulse oximetry and volume-clamp BP reading while subjects wear the devices at different body positions and induce BP changes, during eight visits that will be held over the span of seven days, and generate performance reports.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktiia.product-us
Description: The study will collect data from subjects by means of the device under test and collect data from subjects by means of double-auscultation, pulse oximetry and volume-clamp BP reading while subjects wear the devices at different body positions and induce BP changes, during eight visits that will be held over the span of seven days, and generate performance reports.
Study: NCT06559813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-by-step: A cognitive behavioral parent program with role-plays in virtual reality
Description: A parent training program based on social learning theory and cognitive behavioral therapy (CBT), incorporating virtual reality for training in brief role plays. The program includes similar strategies as other common CBT-parent training programs for parents of children with behavior problems, with the difference that virtual reality is used as an additional way to practice skills.
Study: NCT04836494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-671
Description: BBP-671, oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-671
Description: BBP-671, oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-671
Description: BBP-671, oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BBP-671

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BBP-671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-671
Description: BBP-671, tablet
Study: NCT06445049

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: brief test
Description: The intervention is a simple brief test as follows: With the ventilator set with the patient clinical settings, it will be performed an up to 30sec-long or two inspiratory effort and-expiratory occlusion maneuver on the ventilator and/or switch the patient to pressure support for up to 30sec-long to assess the presence of intrinsic respiratory rate.~If an intrinsic respiratory rate ≥8 breaths per minute is present and P/F ratio is ≥150 it will be performed a 5-minute test in pressure support ventilation with the pressure support level to match the clinical setting of the patient. If the patient tolerates well 5 minutes in pressure support (see criteria below) the clinical team will be informed:~- It will be indicated that the patient tolerated 5 min of PSV and suggest to the clinicians and physician in charge to transition the patient to pressure support ventilation plus suggest reducing sedation.
Study: NCT05003232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) and ICM+
Description: The intervention group will be given continuous NIRS and invasive blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP. Then the goal of blood pressure (within 5 mmHg of CPPopt) will be maintained as the target of blood pressure management for the intervention group during ICU stay.
Study: NCT05301608

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 10 mg of psilocybin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 10 mg of psilocybin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.
Study: NCT05192720

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andosan
Description: See also detailed study design, Mushroom juice based on Agaricus Blazei and two other types of mushroom.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: drinking water with food colour
Study: NCT05095181

Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample

Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample
Study: NCT06130215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple meal management
Description: * Regular meal: Total Carbs per Day x 0.6 / 3~* Large meal: Total Carbs per Day x 0.6 / 3 x 1.5~* Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5
Study: NCT05749185

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency high voltage
Description: nvolved a high voltage PRF technique, where the voltage started at 65 V and could be adjusted up to 80 V based on patient tolerance. Both protocols involved two cycles of PRF application, with each cycle lasting 240 seconds and comprising alternating periods of current application and deactivation. The pulse rate frequency was set at 2 Hertz (Hz), resulting in two active phases/second (20 milliseconds (ms) of current application followed by 480 ms without stimulation)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard RF
Description: A standard voltage PRF technique, administering PRF at a fixed voltage of 45 volts (V)
Study: NCT05972603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1.0 g Vancomycin powder into the wound
Description: 0,35% povidone-iodine solution lavage left for 3 minutes following final implantation and additional application 1.0 g Vancomycin powder into the wound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0,35% povidone-iodine solution lavage
Description: 0,35% povidone-iodine solution lavage left for 3 minutes following final implantation
Study: NCT04914039

Intervention type: COMBINATION_PRODUCT
Intervention: Combination Product
Description: Cases of brain death confirmed by the classic brain death confirmation test

Intervention type: OTHER
Intervention: NO CTA examination
Description: NO CTA examination
Study: NCT04746521

Intervention type: DIAGNOSTIC_TEST
Intervention: Multitest 6 color TBNK and BD Lyotubes
Description: The Multitest 6 color TBNK allows us to count the population-specific B, T, NK cells

Intervention type: BIOLOGICAL
Intervention: genomicDNA extraction
Description: Peripheral blood biospecimens (about 10-15 mL) will be collected through venipuncture in EDTA tubes. Peripheral blood mononuclear cells (PBMCs) will be isolated using Ficoll® Paque Plus (Sigma-Aldrich) centrifugation gradient and genomic DNA will be extracted from fresh PBMCs using DNeasy Blood \& Tissue kit (QIAGEN), according to manufacturer protocols
Study: NCT06130215

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Precise meal management
Description: precise carbohydrate counting for each meal
Study: NCT06028204

Intervention type: DRUG
Intervention: Biologic Agent
Description: Biologic group will have biological agent commenced if considered necessary as part of routine care.
Study: NCT04746521

Intervention type: BIOLOGICAL
Intervention: genomicDNA extraction
Description: Peripheral blood biospecimens (about 10-15 mL) will be collected through venipuncture in EDTA tubes. Peripheral blood mononuclear cells (PBMCs) will be isolated using Ficoll® Paque Plus (Sigma-Aldrich) centrifugation gradient and genomic DNA will be extracted from fresh PBMCs using DNeasy Blood \& Tissue kit (QIAGEN), according to manufacturer protocols
Study: NCT05782088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Piezocision
Description: Piezocision will be performed only once before the onset of canine retraction (T0) on one side of the maxillary arch that will be randomly chosen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repeated Piezocision
Description: Piezocision will be repeated three times, on a monthly basis (T0, T1, and T2), over the 12-week study period.
Study: NCT06150963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Study participants assigned to the VR intervention group were fitted with an HP Reverb G2 Head Mounted Display (HMD) and a wireless mouse prior to preparation for procedure. One virtual environment was utilized, integrating passive and active participant input via gyroscopic motion detection and computer mouse input.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Study participants assigned to the VR intervention group were fitted with an HP Reverb G2 Head Mounted Display (HMD) and a wireless mouse prior to preparation for procedure. One virtual environment was utilized, integrating passive and active participant input via gyroscopic motion detection and computer mouse input.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Procedure Thyroid Biopsy
Description: In this procedure the patient lies down on a bed with their neck tilted back to reveal the thyroid gland. The doctor cleans the skin over the nodule and numbs it with a local anesthetic. The doctor will then use an ultrasound device to visualize the nodule and guide a needle to obtain cells through the syringe. This process may be repeated several times to retrieve adequate tissue for analysis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Procedure Thyroid Biopsy
Description: In this procedure the patient lies down on a bed with their neck tilted back to reveal the thyroid gland. The doctor cleans the skin over the nodule and numbs it with a local anesthetic. The doctor will then use an ultrasound device to visualize the nodule and guide a needle to obtain cells through the syringe. This process may be repeated several times to retrieve adequate tissue for analysis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Procedure PICC Placement
Description: In this procedure the patient lies down on a bed and has their arm cleaned and then numbed with a local anesthetic. The doctor then uses an ultrasound to locate a suitable vein in the arm, typically above the elbow. The physician then makes a small incision in the skin and inserts a needle into the vein, followed by guidance of the Peripherally Inserted Central Catheter (PICC) through the needle until it reaches a large vein near the heart. The final position is confirmed by X-ray and the PICC line is secured at the site of insertion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Procedure PICC Placement
Description: In this procedure the patient lies down on a bed and has their arm cleaned and then numbed with a local anesthetic. The doctor then uses an ultrasound to locate a suitable vein in the arm, typically above the elbow. The physician then makes a small incision in the skin and inserts a needle into the vein, followed by guidance of the Peripherally Inserted Central Catheter (PICC) through the needle until it reaches a large vein near the heart. The final position is confirmed by X-ray and the PICC line is secured at the site of insertion.
Study: NCT05187208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 200mg or 300mg (once daily \[QD\])\*~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD.